CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Ub-RASDisease project investigates targeted degradation of KRAS proteins, which are implicated in many cancers. By developing AlphaTACs, a novel therapeutic approach, the project aims to provide a new method for inhibiting KRAS activity, potentially leading to new cancer treatments.
The RAS pathway is the most frequently activated signaling node in human cancer.
Activating KRAS mutations are found in approximately one in seven human cancers. KRAS signaling is also activated in a significant subset of human cancers that lack KRAS mutations.
Targeting KRAS has been a central goal during the past four decades, and the efforts have intensified over the past years, ignited by the approval of the KRAS-G12C inhibitors. A targeted KRAS degradation approach is an attractive soluti…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
